Weight & metabolism

Orforglipron (Foundayo): the GLP-1 pill, results & how to take it

FDA-approved Checked against official sources Oct 16, 2026

Quick facts

What it is: a once-daily GLP-1 pill (small molecule, not technically a peptide).
Status: FDA-approved April 2026, prescription only, for weight management.
How it's taken: one tablet a day, with or without food, swallowed whole.
Evidence: strong. A 3,127-person Phase 3 trial.
Most common side effects: nausea, constipation, diarrhea, vomiting and other GI effects.

What is Orforglipron?

Orforglipron is a once-daily GLP-1 pill from Eli Lilly, sold as Foundayo. Strictly speaking it isn't a peptide. It's a small molecule that acts on the same GLP-1 receptor as semaglutide. We cover it because it's one of the most-asked-about weight-loss drugs of 2026.

Is Orforglipron FDA-approved?

FDA-approved on April 1, 2026, for weight reduction and long-term maintenance in adults with obesity, or with overweight plus at least one weight-related condition (FDA announcement). Prescription only. The label says not to combine it with another GLP-1 drug.

Foundayo dose schedule: what the FDA label says

Your prescriber sets your dose. This is a summary of the official FDA label to help you follow along, not a plan to start, change, or stop anything.

Foundayo (tablet) — FDA label on DailyMed

Once daily, with or without food. Swallow whole. Don't break, crush, or chew. Never more than one tablet a day.
Starts at 0.8 mg daily. After at least 30 days, 2.5 mg. After at least 30 more days, 5.5 mg.
It can go up to 9 mg, 14.5 mg, or 17.2 mg, each step after at least 30 days, based on response and tolerability. Maximum 17.2 mg daily.
Missed dose: take it as soon as possible. Don't double up. If 7 or more doses in a row are missed, the label says to restart at a lower dose.
Some other medicines (strong CYP3A4 inhibitors or inducers) change the dosing. Tell your prescriber everything you take.

What the research shows

ATTAIN-1 (NEJM, 2025): 3,127 adults with obesity, no diabetes, 72 weeks. Average weight change was −7.5% to −11.2% depending on dose, vs −2.1% on placebo. 5.3–10.3% stopped because of side effects (vs 2.7% on placebo). GI effects were most common.
The trial dose levels (6, 12, 36 mg) don't match the tablet strengths on the U.S. label. Go by the label and your prescriber, not trial numbers.

New to these terms? See the glossary.

Orforglipron FAQ

Is orforglipron FDA-approved?

Yes. FDA approved it as Foundayo on April 1, 2026, for weight reduction and maintenance in certain adults.

Do you take Foundayo with food?

The label says with or without food, once daily, swallowed whole.

What is the Foundayo dose schedule?

Per the label it starts at 0.8 mg daily and steps up at least every 30 days: 2.5 mg, 5.5 mg, then optionally 9, 14.5 or 17.2 mg. Your prescriber sets your dose.

Is orforglipron a peptide?

No. It's a small-molecule drug that acts on the GLP-1 receptor, the same target as semaglutide.

How much weight do people lose on orforglipron?

In ATTAIN-1, average weight change at 72 weeks was −7.5% to −11.2% depending on dose, vs −2.1% on placebo.

Not medical advice. Education only. We don't sell anything or tell you what to take. Label doses are there so you can follow along with your prescriber. Talk to a licensed clinician about your health.

All guides: Semaglutide · Tirzepatide · Retatrutide · BPC-157 · TB-500 (thymosin beta-4) · GHK-Cu (copper peptide) · Collagen peptides · Tesamorelin (Egrifta) · CJC-1295 & ipamorelin · MOTS-c · Semax · PT-141 (bremelanotide, Vyleesi) · Peptides 101 · Why is peptide info so confusing?